GetTopicDetailResponse(id=9e6d925e94c, topicName=資訊, introduction=資訊, content=null, image=null, comments=1, allHits=1422, url=https://h5.medsci.cn/topic?id=92579, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=24416, tagList=[TagDto(tagId=24416, tagName=資訊)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1198785, encodeId=15d21198e8504, content=這篇資訊很棒<a href='/topic/show?id=9e6d925e94c' target=_blank style='color:#2F92EE;'>#資訊#</a> , objectTitle=J Immunother Cancer：Toripalimab（特瑞普利單抗）聯(lián)合axitinib（阿昔替尼）治療轉移性粘膜黑色素瘤的3年生存更新結果, objectType=article, longId=299734, objectId=92ab299e343d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022227/1645944512030_1611618.jpg, objectUrl=/article/show_article.do?id=92ab299e343d, replyNumber=0, likeNumber=139, createdTime=2022-03-02, rootId=0, userName=Mr liu CJ, userId=0ecd5161828, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ab299e343d, moduleTitle=J Immunother Cancer：Toripalimab（特瑞普利單抗）聯(lián)合axitinib（阿昔替尼）治療轉移性粘膜黑色素瘤的3年生存更新結果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=92ab299e343d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
